George J. Hanna

Statistics

Publications

Citations

4.9K

H-Index

Active since

1998

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Bristol-Myers Squibb (United States)

Université Paris Cité

Harvard University

Hôpital Saint-Louis

George J. Hanna is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in antiviral therapy, antiretroviral therapy, and virology.

ORCID

Publications per year

1998–2023

Publications

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

Sarah Palmer, Frank Maldarelli, Ann Wiegand et al. · Proceedings of the National Academy of Sciences · 2008 · 646 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +14

ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia

Frank Maldarelli, Sarah Palmer, Martin King et al. · PLoS Pathogens · 2007 · 334 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +16

Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy

Lee T. Bacheler, Susan Jeffrey, George J. Hanna et al. · Journal of Virology · 2001 · 240 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Antiretroviral resistance during successful therapy of HIV type 1 infection

Javier Martínez‐Picado, Maria Pia DePasquale, Nicholas A. Kartsonis et al. · Proceedings of the National Academy of Sciences · 2000 · 212 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

Boris Jülg, Lynda Dee, Jintanat Ananworanich et al. · The Lancet HIV · 2019 · 206 citations

Pharmacy, Pharmacotherapy, Good Clinical Practice +12

1–5 of 68